+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Axial spondyloarthritis (axSpA) Market and Forecast Analysis to 2037

  • ID: 4418863
  • Drug Pipelines
  • July 2018
  • Region: Global
  • 393 Pages
  • Datamonitor Healthcare
1 of 2
Disease Overview
Axial spondyloarthritis (axSpA) is a chronic, systemic, inflammatory rheumatic disease that predominantly affects the spine and sacroiliac (SI) joints, leading to chronic back pain. The chronic inflammation can eventually result in new bone formation in the SI joints and spine, causing permanent impairment in spinal mobility. Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) are the two sub-diseases that comprise axSpA.

Market Snapshot
  • Uptake of IL inhibitors and US price increases will drive market growth despite downward pressure from biosimilars.
  • Biologic DMARDs are prescribed with increasing frequency as patients move through the axSpA treatment algorithm.
  • Total prevalent cases of axSpA are expected to increase by almost 10% in the US, Japan, and five major EU markets by 2037.
  • Cosentyx has seen strong uptake due to its ability to meet an unmet medical need in TNF-refractory patients.
  • A currently limited pipeline leaves room for developers of novel agents targeting the TNF-refractory population.
Note: Product cover images may vary from those shown
2 of 2
FORECAST: AXIAL SPONDYLOARTHRITIS (Published on 18 May 2018)
Overview
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Cimzia
Product Profile: Cosentyx
Product Profile: Enbrel
Product Profile: Humira
Product Profile: Remicade
Product Profile: Simponi
Product Profile (Late Stage): Taltz

TREATMENT: AXIAL SPONDYLOARTHRITIS (Published on 18 May 2018)
Overview
Primary Research Methodology
Disease Definition And Diagnosis
Current Treatment Options
Prescribing Trends
Compliance
Treatment Challenges And Unmet Needs
Impact Of Pipeline Agents
Impact Of Biosimilars

EPIDEMIOLOGY: AXIAL SPONDYLOARTHRITIS (Published on 17 July 2018)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources

MARKETED DRUGS: AXIAL SPONDYLOARTHRITIS (Published on 18 May 2018)
Overview
Executive Summary
Product Overview
Product Profile: Cimzia
Product Profile: Cosentyx
Product Profile: Enbrel
Product Profile: Humira
Product Profile: Remicade
Product Profile: Simponi

PIPELINE: AXIAL SPONDYLOARTHRITIS (Published on 18 May 2018)
Overview
Executive Summary
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Otezla
Product Profile (Late Stage): Taltz

LIST OF FIGURES
Figure 1: Axial spondyloarthritis – current and future market dynamics analysis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for axial spondyloarthritis
Figure 3: Total market sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 4: Total axial spondyloarthritis sales across the five major EU markets, by country, 2016–25
Figure 5: Total axial spondyloarthritis sales according to drug class, 2016–25
Figure 6: Sales of Enbrel and Humira versus other established biologics within axial spondyloarthritis in the US, Japan, and five major EU markets, 2016–25
Figure 7: Total axial spondyloarthritis patients across the US, Japan, and five major EU markets, by drug class, 2016–25
Figure 8: Total sales of Cosentyx versus Cimzia and Simponi for axial spondyloarthritis in the US, Japan, and five major EU markets, 2016–25
Figure 9: The authors axial spondyloarthritis forecast methodology
Figure 10: Price sources and calculations, by country
Figure 11: Cimzia for axial spondyloarthritis – SWOT analysis
Figure 12: The authors drug assessment summary of Cimzia in axial spondyloarthritis
Figure 13: The authors drug assessment summary of Cimzia in axial spondyloarthritis
Figure 14: Cimzia sales for axial spondyloarthritis across the US and five major EU markets, by country, 2016–25
Figure 15: Cosentyx for axial spondyloarthritis – SWOT analysis
Figure 16: The authors drug assessment summary of Cosentyx in axial spondyloarthritis
Figure 17: The authors drug assessment summary of Cosentyx in axial spondyloarthritis
Figure 18: Cosentyx sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 19: Enbrel for axial spondyloarthritis – SWOT analysis
Figure 20: The authors drug assessment summary of Enbrel in axial spondyloarthritis
Figure 21: The authors drug assessment summary of Enbrel in axial spondyloarthritis
Figure 22: Enbrel sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 23: Humira for axial spondyloarthritis – SWOT analysis
Figure 24: The authors drug assessment summary of Humira in axial spondyloarthritis
Figure 25: The authors drug assessment summary of Humira in axial spondyloarthritis
Figure 26: Humira sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 27: Remicade for axial spondyloarthritis – SWOT analysis
Figure 28: The authors drug assessment summary of Remicade in axial spondyloarthritis
Figure 29: The authors drug assessment summary of Remicade in axial spondyloarthritis
Figure 30: Remicade sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 31: Simponi for axial spondyloarthritis – SWOT analysis
Figure 32: The authors drug assessment summary of Simponi in axial spondyloarthritis
Figure 33: The authors drug assessment summary of Simponi in axial spondyloarthritis
Figure 34: Simponi and Simponi Aria sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 35: Taltz for axial spondyloarthritis – SWOT analysis
Figure 36: The authors drug assessment summary of Taltz in axial spondyloarthritis
Figure 37: The authors drug assessment summary of Taltz in axial spondyloarthritis
Figure 38: Taltz sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 39: Proportion of ankylosing spondylitis patients and non-radiographic axial spondyloarthritis patients, by country (%)
Figure 40: Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis
Figure 41: Diagnosed versus undiagnosed axial spondyloarthritis patients, by country (%)
Figure 42: Diagnosed axial spondyloarthritis patients treated by each type of healthcare professional, by country (%)
Figure 43: Type of therapy received by diagnosed axial spondyloarthritis patients, by country (%)
Figure 44: Treated axial spondyloarthritis patients receiving monotherapy versus combination therapy, by country (%)
Figure 45: Distribution of axial spondyloarthritis patients according to monotherapy/combination use, by country (%)
Figure 46: Top four regimens used for the treatment of first-line axial spondyloarthritis patients, by country (%)
Figure 47: Top four biologic disease-modifying antirheumatic drugs used for the treatment of first-line axial spondyloarthritis patents, by country (%)
Figure 48: Total combined biologic disease-modifying antirheumatic drug use for the treatment of axSpA patients at each line of therapy, by country (%)
Figure 49: Total combined use of Remicade across all lines of therapy for the treatment of axial spondyloarthritis, by country (%), 2014 and 2016
Figure 50: Top four biologic disease-modifying antirheumatic drugs prescribed in Japan for the treatment of axial spondyloarthritis patients after conventional DMARDs, by line of therapy (%)
Figure 51: Top five biologic disease-modifying antirheumatic drugs used for the treatment of second-line axial spondyloarthritis patients, by country (%)
Figure 52: All prescribed biologic DMARDs used for the treatment of third-line axial spondyloarthritis patients after conventional DMARDs, by country (%)
Figure 53: All prescribed biologic DMARDs used for the treatment of fourth-line and later axial spondyloarthritis patients, by country (%)
Figure 54: Compliance rate for axial spondyloarthritis treatment, by formulation type and country (%)
Figure 55: Top three treatment challenges in axial spondyloarthritis
Figure 56: Expected market shares of DMARD-treated axial spondyloarthritis patients for currently approved and pipeline agents five years after launch, by country (%)
Figure 57: Physician confidence in prescribing biosimilars for axial spondyloarthritis approved on the basis of indication extrapolation, by country (%)
Figure 58: Summary of future usage of biosimilars at one year and three years post-launch (%)
Figure 59: Taxonomy of spondyloarthritis
Figure 60: ASAS classification criteria for axial spondyloarthritis
Figure 61: Trends in total prevalent cases of axial spondyloarthritis in the US, Japan, and five major EU markets, by country, 2017–37
Figure 62: Cimzia for axial spondyloarthritis – SWOT analysis
Figure 63: The authors drug assessment summary of Cimzia in axial spondyloarthritis
Figure 64: The authors drug assessment summary of Cimzia in axial spondyloarthritis
Figure 65: Cimzia sales for axial spondyloarthritis across the US and five major EU markets, by country, 2016–25
Figure 66: Cosentyx for axial spondyloarthritis – SWOT analysis
Figure 67: The authors drug assessment summary of Cosentyx in axial spondyloarthritis
Figure 68: The authors drug assessment summary of Cosentyx in axial spondyloarthritis
Figure 69: Cosentyx sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 70: Enbrel for axial spondyloarthritis – SWOT analysis
Figure 71: The authors drug assessment summary of Enbrel in axial spondyloarthritis
Figure 72: The authors drug assessment summary of Enbrel in axial spondyloarthritis
Figure 73: Enbrel sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 74: Humira for axial spondyloarthritis – SWOT analysis
Figure 75: The authors drug assessment summary of Humira in axial spondyloarthritis
Figure 76: The authors drug assessment summary of Humira in axial spondyloarthritis
Figure 77: Humira sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 78: Remicade for axial spondyloarthritis – SWOT analysis
Figure 79: The authors drug assessment summary of Remicade in axial spondyloarthritis
Figure 80: The authors drug assessment summary of Remicade in axial spondyloarthritis
Figure 81: Remicade sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 82: Simponi for axial spondyloarthritis – SWOT analysis
Figure 83: The authors drug assessment summary of Simponi in axial spondyloarthritis
Figure 84: The authors drug assessment summary of Simponi in axial spondyloarthritis
Figure 85: Simponi and Simponi Aria sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 86: Taltz for axial spondyloarthritis – SWOT analysis
Figure 87: The authors drug assessment summary of Taltz in axial spondyloarthritis
Figure 88: The authors drug assessment summary of Taltz in axial spondyloarthritis
Figure 89: Taltz sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25

LIST OF TABLES
Table 1: Total market sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 2: Total axial spondyloarthritis sales according to drug class ($m), 2016–25
Table 3: Total axial spondyloarthritis patients across the US, Japan, and five major EU markets, by drug class, 2016–25
Table 4: Total sales of cDMARDs methotrexate and sulfasalazine across the US, Japan, and five major EU markets ($m), 2016–25
Table 5: Sales of Cosentyx versus Taltz for axial spondyloarthritis in the US, Japan, and five major EU markets ($m), 2016–25
Table 6: Exchange rates used for calculating prices
Table 7: Rheumatologists surveyed for the axial spondyloarthritis primary research study, 2016
Table 8: Cimzia drug profile
Table 9: Cimzia pivotal trial data in axial spondyloarthritis
Table 10: Cimzia ongoing late-phase trial in axial spondyloarthritis
Table 11: Cimzia sales for axial spondyloarthritis across the US and five major EU markets, by country ($m), 2016–25
Table 12: Cosentyx drug profile
Table 13: Cosentyx pivotal trial data in axial spondyloarthritis
Table 14: Late-phase trials for Cosentyx in axial spondyloarthritis
Table 15: Ongoing late-phase trials for Cosentyx in axial spondyloarthritis
Table 16: Cosentyx sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 17: Enbrel drug profile
Table 18: Enbrel pivotal trial data in axial spondyloarthritis
Table 19: Enbrel late-phase trial data in axial spondyloarthritis
Table 20: Enbrel sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 21: Humira drug profile
Table 22: Humira pivotal trial data in axial spondyloarthritis
Table 23: Humira late-phase trial data in axial spondyloarthritis
Table 24: Humira sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 25: Remicade drug profile
Table 26: Remicade pivotal trial data in axial spondyloarthritis
Table 27: Remicade sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 28: Simponi drug profile
Table 29: Simponi pivotal trial data in axial spondyloarthritis
Table 30: Simponi Aria pivotal trial data in axial spondyloarthritis
Table 31: Simponi and Simponi Aria sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 32: Taltz drug profile
Table 33: Taltz Phase III trials in axial spondyloarthritis
Table 34: Taltz sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 35: Rheumatologists surveyed for the axial spondyloarthritis primary research study, March 2016
Table 36: Key generic conventional disease-modifying antirheumatic drugs for the treatment of axial spondyloarthritis
Table 37: Key marketed biologic disease-modifying antirheumatic drugs for the treatment of axial spondyloarthritis
Table 38: Total combined usage of methotrexate and sulfasalazine, as monotherapies and combinations, for treatment of axSpA, by line of therapy and country (%)
Table 39: Total combined biologic disease-modifying antirheumatic drug use for the treatment of axSpA patients at each line of therapy, by country (%)
Table 40: Current usage of biosimilar infliximab, according to respondents currently prescribing the biosimilar, by country (%)
Table 41: Compliance rate for axial spondyloarthritis treatment, by formulation type and country (%)
Table 42: Relative importance of treatment challenges in axial spondyloarthritis
Table 43: Future usage of biosimilar infliximab, according to respondents aware of biosimilars, by country (%)
Table 44: Sources used for the epidemiological analysis of ankylosing spondylitis in the US, Japan, and five major EU markets, by country
Table 45: Total prevalent cases of axial spondyloarthritis in the US, Japan, and five major EU markets, by country, 2017–37
Table 46: Profiled key marketed drugs for axial spondyloarthritis
Table 47: Cimzia drug profile
Table 48: Cimzia pivotal trial data in axial spondyloarthritis
Table 49: Cimzia ongoing late-phase trial in axial spondyloarthritis
Table 50: Cimzia sales for axial spondyloarthritis across the US and five major EU markets, by country ($m), 2016–25
Table 51: Cosentyx drug profile
Table 52: Cosentyx pivotal trial data in axial spondyloarthritis
Table 53: Late-phase trials for Cosentyx in axial spondyloarthritis
Table 54: Ongoing late-phase trials for Cosentyx in axial spondyloarthritis
Table 55: Cosentyx sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 56: Enbrel drug profile
Table 57: Enbrel pivotal trial data in axial spondyloarthritis
Table 58: Enbrel late-phase trial data in axial spondyloarthritis
Table 59: Enbrel sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 60: Humira drug profile
Table 61: Humira pivotal trial data in axial spondyloarthritis
Table 62: Humira late-phase trial data in axial spondyloarthritis
Table 63: Humira sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 64: Remicade drug profile
Table 65: Remicade pivotal trial data in axial spondyloarthritis
Table 66: Remicade sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 67: Simponi drug profile
Table 68: Simponi pivotal trial data in axial spondyloarthritis
Table 69: Simponi Aria pivotal trial data in axial spondyloarthritis
Table 70: Simponi and Simponi Aria sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 71: Profiled pipeline products in development for axial spondyloarthritis
Table 72: Otezla drug profile
Table 73: Otezla Phase III data in axial spondyloarthritis
Table 74: Taltz drug profile
Table 75: Taltz Phase III trials in axial spondyloarthritis
Table 76: Taltz sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Note: Product cover images may vary from those shown
Adroll
adroll